Therapeutic leverage: de-escalation and barrier restoration

Two prevention predictions fall out of the same kernel. Because synergistic carcinogens MULTIPLY risk, removing one DIVIDES it: dropping HBV from aflatoxin×HBV cuts RR 72→6.4 (11.3×), not the 6.4× additive thinking expects. And restoring the barrier by δ suppresses crossing by e^(−δ/D) — exponential, so prevention dominates cure. Grade [H] on [F]/[V]/[L].

The carcinogenesis kernel makes two quantitative prevention/treatment predictions. De-escalation: removing one of two multiplicative drivers divides the combined risk by that driver's RR (a retrodiction matching the large benefit of HBV control in aflatoxin regions). Barrier restoration: the Kramers rate makes barrier-raising suppress malignant crossing exponentially, so small reductions in drive have outsized effect.

De-escalation: removing a driver divides the risk

The headline synergy result (§9) is that additive barrier decrements make carcinogen risks multiply: aflatoxin RR 6.37 × HBV RR 11.3 = combined 72. Read backwards, this is a prevention statement. Removing one driver does not subtract its excess risk — it divides the combined risk by that driver's RR. Eliminating HBV (vaccination, antivirals) takes the combined RR from 72 to 6.4, a 11.3-fold reduction; naive additive thinking would predict only 62 (a 1.17-fold change). The framework therefore predicts a dramatic, multiplicative benefit from removing one synergistic exposure — which matches the observed super-additive drop in hepatocellular carcinoma where HBV is controlled in aflatoxin-exposed populations.

Barrier restoration: why prevention beats cure, exponentially

The malignant-crossing rate is Kramers, k = k₀ e^(−barrier/D). Any intervention that raises the effective barrier by δ — reducing the carcinogen drive (prevention), or a partial barrier-restoring agent — suppresses the crossing rate by e^(−δ/D). The suppression is exponential, not proportional: with D=0.10, restoring the barrier by 0.2 gives ~7× fewer crossings and by 0.5 gives ~148×, where a linear expectation would predict barely a 1.3× effect. The log-suppression is linear in δ with slope −1/D (-10.0). The implication is that keeping the barrier high (low drive) suppresses transformation far more than fighting an already-transformed population — the quantitative case for prevention, and for barrier-restoring rather than purely cytotoxic strategies.

Status

De-escalation (T20) is the most robust prediction — an epidemiological retrodiction — graded [V] against the cited HBV-control benefit [L]. The barrier-restoration leverage (T21) is forced by the Kramers form [F]. Both inherit the [O]/[H] caveat of §20: their clinical force depends on the barrier really being γ²/4 from promoter stacking energy. These are testable targets and public-health predictions, not clinical recommendations.